# Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

> **NCT00332280** · PHASE2,PHASE3 · TERMINATED · sponsor: **Auron Healthcare GmbH** · enrollment: 67 (actual)

## Conditions studied

- Gastrointestinal Cancer
- Prostate Cancer
- Genital Neoplasms, Female

## Interventions

- **DRUG:** AMT2003

## Key facts

- **NCT ID:** NCT00332280
- **Lead sponsor:** Auron Healthcare GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2010-01
- **Final completion:** 2010-03
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** Lack of efficacy. Stopped at first interim evaluation point
- **Last updated:** 2013-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332280, "Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00332280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*